Form 8-K - Current report:
SEC Accession No. 0001104659-23-069929
Filing Date
2023-06-09
Accepted
2023-06-09 16:25:24
Documents
13
Period of Report
2023-06-08
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2318328d1_8k.htm   iXBRL 8-K 48977
2 EXHIBIT 3.1 tm2318328d1_ex3-1.htm EX-3.1 32383
  Complete submission text file 0001104659-23-069929.txt   266429

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrsn-20230608.xsd EX-101.SCH 3030
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrsn-20230608_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrsn-20230608_pre.xml EX-101.PRE 22593
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2318328d1_8k_htm.xml XML 3596
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38129 | Film No.: 231005667
SIC: 2834 Pharmaceutical Preparations